AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 192 min read$MANE

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results

Veradermics (NYSE:MANE) reported positive results from its Phase III trial for VDPHL01 in male pattern hair loss, meeting all endpoints. The trial showed strong growth with mild to moderate adverse events. The company plans to release extension data from Study 302 later this year and expects results from a female pattern hair loss study in 2027. Veradermics has $820 million in cash and is evaluating regulatory filing strategies.

Original reporting
finance.yahoo.com
Published Oct 19, 2026, 5:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 5:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MANEBullishHigh
01

Why it matters

The trial data provides the first robust efficacy signal, likely prompting analyst upgrades and increased trading volume.

02

Market read

Positive Phase III results are a primary catalyst that can move the stock sharply in the short term.

03

What to watch

Potential competition from generic oral minoxidil and pricing premium could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: today

Background

Veradermics (NYSE:MANE) is a clinical‑stage company focused on dermatologic therapies. The VDPHL01 program targets male and female pattern hair loss.

Company-level read

Ticker impact

$MANEBullishHigh confidence
Context

Veradermics reported positive Phase III trial results for VDPHL01, meeting all endpoints and showing strong growth potential.

Expected impact

upward pressure as market prices in potential approval and commercial rollout

Evidence & confidence

Phase III success is a material catalyst for a clinical‑stage biotech, often driving immediate price appreciation.

Market effects

Sector

Strengthens outlook for dermatology biotech sector and may boost peer valuations.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Potentially relevant to global investors tracking dermatology treatments.

Counterpoint

What could challenge this read

If regulatory hurdles arise or market pricing already anticipates approval, upside may be limited.

Key entities

  • company
    Veradermics, Inc.

    Clinical‑stage biopharma developing VDPHL01 for hair loss.

  • executive
    Mark Neumann

    Chief Commercial and Strategy Officer who presented market research results.

Read at source← All news

StoryVeradermics reports Phase 3 trial success for oral hair‑loss drug VDPHL01

Also covered by

1 outlet

Related articles

OCT 19
MedAI 9/10

Veradermics’ stock up on male hair loss trial success

Veradermics' stock rose 6% after its Phase III trial for male hair loss drug VDPHL01 met all endpoints, showing significant hair growth vs. placebo. The drug was well-tolerated, with 78.8% and 85.0% of patients reporting improvement in once-daily and twice-daily arms, respectively. Veradermics aims for FDA approval, potentially becoming the first oral pill for pattern hair loss in 30 years.

finance.yahoo.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment

Veradermics (MANE) shares rose 10% after its oral hair-loss pill, VDPHL01, met all primary and secondary goals in a second Phase 3 trial. The pill increased hair count significantly compared to placebo with no serious cardiac events. The company expects 12-month safety data later this year. Veradermics has sufficient cash to potentially reach a launch, according to management.

finance.yahoo.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics Stock Rises 7% After Positive Phase 3 Hair Loss Trial Results

Veradermics (MANE) stock rose 6.98% to $116.42 after positive Phase 3 trial results for its hair loss treatment VDPHL01, meeting all endpoints with statistical significance. The trial involved 536 males with mild-to-moderate hair loss, showing significant hair count increases compared to placebo. The company expects further data later this year and in 2027.

rttnews.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics posts positive Phase 3 '304' topline: VDPHL01 raises hair count up to 36.4 hairs/cm², no treatment‑related SAEs

Veradermics (MANE) reported positive Phase 3 results for VDPHL01, showing significant hair growth and a favorable safety profile. The study met all endpoints, with hair count increases of 28.6 (QD) and 36.4 (BID) hairs/cm² vs. 6.6 for placebo. Patient-reported improvements were 78.8% (QD) and 85.0% (BID) vs. 35.3% for placebo. No treatment-related serious adverse events were reported.

tradingview.com1 min
OCT 19
$MANEHighAI 8/10

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss

Veradermics, Inc (MANE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with h

SEC EDGAR 8-K2 min